Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial
| Autor: | Rovati, L.C.; Brambilla, N.; Blicharski, T.; Connell, J.; Vitalini, C.; Bonazzi, A.; Giacovelli, G.; Girolami, F.; D'Amato, M. |
|---|---|
| Sprache: | Englisch |
| Veröffentlicht: |
2020 |
| Quelle: | ScienceDirect (Elsevier) |
| Online Zugang: |
http://dx.doi.org/10.1016/j.joca.2019.09.002 https://api.elsevier.com/content/article/PII:S1063458419312087?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S1063458419312087?httpAccept=text/plain |
| Erfassungsnummer: | crelsevierbv:10.1016/j.joca.2019.09.002 |